Search Results - "Allué, Jose A"
-
1
Aβ42/Aβ40 ratio in plasma predicts amyloid‐PET status in amnestic‐MCI patients
Published in Alzheimer's & dementia (01-12-2021)“…Background We have completed the analytical validation of an antibody‐free, HPLC‐MS/MS method (ABtest‐MS), to quantitate specifically Aβ1‐40 and Aβ1‐42 in…”
Get full text
Journal Article -
2
AB1601 Phase 2 Study of ABvac40, an Anti‐Aβ40 Vaccine: Safety and Immunogenicity of a Cross‐Over Extension
Published in Alzheimer's & dementia (01-12-2023)“…Background Amyloid‐β (Aβ) immunotherapy is a promising strategy for treating Alzheimer’s disease (AD). Previous studies suggested that Aβ40 could have an…”
Get full text
Journal Article -
3
AB1601 topline results – Phase 2 study of ABvac40 in patients with amnestic mild cognitive impairment (a‐MCI) or very mild Alzheimer’s Disease (Vm‐AD)
Published in Alzheimer's & dementia (01-12-2022)“…Background Immunotherapy against amyloid β (Aβ) has emerged as a promising treatment option for Alzheimer’s disease (AD). Araclon‐Biotech is developing an…”
Get full text
Journal Article -
4
Contribution of clinical information to the predictive performance of plasma Aβ levels for Aβ PET positivity
Published in Alzheimer's & dementia (01-12-2023)“…Background Early detection of β‐amyloid (Aβ) accumulation, a major biomarker for Alzheimer’s disease (AD), has become important. While Aβ deposition can be…”
Get full text
Journal Article -
5
Safety, tolerability and immunogenicity of an active anti‐Aβ40 vaccine (ABvac40) in patients with amnestic mild cognitive impairment (A‐MCI) or very mild alzheimer’s disease (VM‐AD): A randomized, double‐blind, placebo‐controlled, phase II trial
Published in Alzheimer's & dementia (01-12-2020)“…Background Alzheimer's disease is one of the biggest burdens of society with a dramatic and growing worldwide incidence rate. Notwithstanding scientific and…”
Get full text
Journal Article -
6
Safety, tolerability and immunogenicity of an active anti‐Aβ40 vaccine (ABvac40) in patients with amnestic mild cognitive impairment (A‐MCI) or very mild alzheimer’s disease (VM‐AD): A randomized, double‐blind, placebo‐controlled, phase II trial: Human/Human trials: Anti‐amyloid
Published in Alzheimer's & dementia (01-12-2020)Get full text
Journal Article -
7
Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers
Published in Alzheimer's & dementia (01-12-2021)“…Background Recent data suggest that blood biomarkers of amyloid‐β (Aβ) pathology (Aβ42/Aβ40), tau pathology (phosphorylated tau [P‐tau]) and neurodegeneration…”
Get full text
Journal Article -
8
Beta-amyloid-17 is a major beta-amyloid fragment isoform in cerebrospinal fluid and blood that shows diagnostic value
Published in Alzheimer's & dementia (01-07-2012)Get full text
Journal Article -
9
O2‐03‐05: Beta‐amyloid‐17 is a major beta‐amyloid fragment isoform in cerebrospinal fluid and blood that shows diagnostic value
Published in Alzheimer's & dementia (01-07-2012)Get full text
Journal Article